Phathom Pharmaceuticals, Inc. Financing cash flow

Financing cash flow of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Financing cash flow growth rates and interactive chart.


Highlights and Quick Summary

  • Financing cash flow for the quarter ending June 29, 2021 was $104 Thousand (a -74.76% decrease compared to previous quarter)
  • Year-over-year quarterly Financing cash flow increased by Infinity%
  • Annual Financing cash flow for 2020 was $114 Million (a -62.5% decrease from previous year)
  • Annual Financing cash flow for 2019 was $305 Million (a 15919.82% increase from previous year)
  • Twelve month Financing cash flow ending June 29, 2021 was $89.8 Million (a 0.12% increase compared to previous quarter)
  • Twelve month trailing Financing cash flow decreased by -58.78% year-over-year
Trailing Financing cash flow for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
$89.8 Million $89.7 Million $114 Million $218 Million
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Financing cash flow of Phathom Pharmaceuticals, Inc.

Most recent Financing cash flowof PHAT including historical data for past 10 years.

Interactive Chart of Financing cash flow of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Financing cash flow for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $0.1 $0.41
2020 $89.25 $0.0 $0.0 $25.0 $114.25
2019 $192.77 $-1.3 $113.17 $304.7
2018 $1.05 $0.85 $1.9

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.